Trimebutine

Synonyms: 曲美布汀
Trimebutine 是一种多靶点抑制剂和阿片受体 (Opioid Receptor) 激动剂,具有抗毒蕈碱活性,可抑制 L 型钙通道 (L-type Ca2+ channels) 和大电导钙激活钾通道 (BKCa channels),从而抑制细胞外钙内流及钾离子外流,还靶向 Toll 样受体,通过抑制 Toll-like receptor 2/4/7/8/9 信号来抑制 LPS 诱导的 IRAK1 激活以及 ERK1/2、JNK 和 NF-κB 的激活,从而发挥抗炎作用,并通过抑制 AKT/ERK 通路诱导肿瘤细胞凋亡 (apoptosis),同时抑制平滑肌过度收缩,可用于肠易激综合征 (IBS) 等胃肠道功能紊乱的研究。
产品编号: MS-F19078 纯度: 99.42% CAS No.: 39133-31-8 分子式: C22H29NO5 分子量: 387.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Trimebutine 是一种多靶点抑制剂和阿片受体 (Opioid Receptor) 激动剂,具有抗毒蕈碱活性,可抑制 L 型钙通道 (L-type Ca2+ channels) 和大电导钙激活钾通道 (BKCa channels),从而抑制细胞外钙内流及钾离子外流,还靶向 Toll 样受体,通过抑制 Toll-like receptor 2/4/7/8/9 信号来抑制 LPS 诱导的 IRAK1 激活以及 ERK1/2、JNK 和 NF-κB 的激活,从而发挥抗炎作用,并通过抑制 AKT/ERK 通路诱导肿瘤细胞凋亡 (apoptosis),同时抑制平滑肌过度收缩,可用于肠易激综合征 (IBS) 等胃肠道功能紊乱的研究。

生物实验数据

生物活性 Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity that inhibits L-type Ca2+ channels and large-conductance Ca2+-activated K+ (BKCa) channels, thereby suppressing extracellular calcium influx and potassium efflux, and also targets Toll-like receptors by inhibiting Toll-like receptor 2/4/7/8/9 signaling to suppress LPS-induced IRAK1 activation as well as ERK1/2, JNK, and NF-κB activation, thus exerting anti-inflammatory effects, and induces tumor cell apoptosis via inhibition of the AKT/ERK pathway while also inhibiting excessive smooth muscle contraction, making it useful for research on gastrointestinal disorders such as irritable bowel syndrome (IBS).
IC50 & Target

μ Opioid Receptor/MOR

 

L-type calcium channel

 

IRAK-1

 

ERK1

 

ERK2

 

体外研究
(In Vitro)

Trimebutine (0-1000 μM;48 h) 中可显著抑制 SHG44、U251、U-87 MG 胶质瘤细胞活力,IC50 分别为 98.28 μM、128.27 μM、204.06 μM,对正常 HEB 细胞毒性较低。
Trimebutine (0-200 μM;24-72 h) 可抑制 U-87 MG 细胞迁移,呈浓度和时间依赖性。
Trimebutine (0-200 μM;48-72 h) 可诱导胶质瘤细胞凋亡,下调 Bcl-2、上调 Bax 并激活 Caspase-3,同时抑制 AKT (Ser473) 和 ERK (Thr202/Tyr204) 磷酸化。

Cell Viability Assay

Cell Line: SHG44, U251, U-87 MG
Concentration: 0, 10, 50, 100, 200 μM
Incubation Time: 48 h and 72 h
Result: Reduced phosphorylated AKT (Ser473) and ERK (Thr202/Tyr204) levels in a dose-dependent manner at both time points, while total AKT and ERK protein levels remained unchanged.
The inhibition was more pronounced at 72 h for higher concentrations (100-200 μM).
体内研究
(In Vivo)

Trimebutine (100 mg/kg/day;腹腔注射;每天 1 次;7 d) 抑制雌性裸鼠 U-87 MG 胶质瘤皮下异种抑制模型的肿瘤生长,增加肿瘤组织中 TUNEL 阳性凋亡细胞,下调 Bcl-2、上调 Bax,并抑制 p-AKT 和 p-ERK 信号通路。
Trimebutine (50 mg/kg;口服;单剂量) 处理 4 小时后,显著降低雄性小鼠结肠直肠扩张模型中 60 mmHg 压力下的痛觉反应,整体效果弱于等摩尔剂量的 GIC-1001 (MS-C49716)。

Animal Model:
Dosage:
Administration:
Result: Animal Model: Female nude mice (4-week-old), subcutaneous U-87 MG glioblastoma xenograft model Dosage (solvent): 100 mg/kg/day (DMSO) Administration: Intraperitoneal injection (i.p.), once daily for 7 days, starting when tumors reached ~2 mm3; monitored at days 7, 10, 14, 16, 18, 21. Result: Significantly reduced tumor volume compared to the vehicle control group, with final tumor weight decreasing by ~30%. Histological analysis showed increased TUNEL-positive apoptotic cells in tumor sections.
Downregulated Bcl-2 and upregulated Bax protein levels, along with reduced phosphorylation of AKT (Ser473) and ERK (Thr202/Tyr204), indicating modulation of apoptotic and proliferative signaling pathways.
No significant toxicity was observed in treated mice, as body weight and general activity remained comparable to controls.
Animal Model: Female nude mice (4-week-old), subcutaneous U-87 MG glioblastoma xenograft model
Dosage: 100 mg/kg/day
Administration: Intraperitoneal injection (i.p.), once daily for 7 days, starting when tumors reached ~2 mm3; monitored at days 7, 10, 14, 16, 18, 21.
Result: Significantly reduced tumor volume compared to the vehicle control group, with final tumor weight decreasing by ~30%. Histological analysis showed increased TUNEL-positive apoptotic cells in tumor sections.
Downregulated Bcl-2 and upregulated Bax protein levels, along with reduced phosphorylation of AKT (Ser473) and ERK (Thr202/Tyr204), indicating modulation of apoptotic and proliferative signaling pathways.
No significant toxicity was observed in treated mice, as body weight and general activity remained comparable to controls.
性状 固体
颜色 White to off-white

化学信息

分子量 387.47
分子式 C22H29NO5
CAS No. 39133-31-8
别名 曲美布汀

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (258.08 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.5808 mL12.9042 mL25.8084 mL64.5211 mL
5 mM0.5162 mL2.5808 mL5.1617 mL12.9042 mL
10 mM0.2581 mL1.2904 mL2.5808 mL6.4521 mL
15 mM0.1721 mL0.8603 mL1.7206 mL4.3014 mL
20 mM0.1290 mL0.6452 mL1.2904 mL3.2261 mL
25 mM0.1032 mL0.5162 mL1.0323 mL2.5808 mL
30 mM0.0860 mL0.4301 mL0.8603 mL2.1507 mL
40 mM0.0645 mL0.3226 mL0.6452 mL1.6130 mL
50 mM0.0516 mL0.2581 mL0.5162 mL1.2904 mL
60 mM0.0430 mL0.2151 mL0.4301 mL1.0754 mL
80 mM0.0323 mL0.1613 mL0.3226 mL0.8065 mL
100 mM0.0258 mL0.1290 mL0.2581 mL0.6452 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

曲美布汀 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础